Preoperative Prediction of Multifocal Prostate Cancer and Application of Focal Therapy: Review 2007

Urology

Volumn 70, Issue 6 SUPPL. 1, 2007, Pages

  Meiers, Isabelle ^a   Waters, David J ^b   Bostwick, David G ^a  

^a BOSTWICK LABORATORIES   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DIGITAL RECTAL EXAMINATION; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

BIOPSY; HUMANS; MALE; MEDICAL ONCOLOGY; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK;

EID: 38049010321     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.06.1129     Document Type: Article

References (64)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Albertsen P.C. PSA and the conservative treatment of early prostate cancer. Arch Ital Urol Androl 78 (2006) 152-153
3. Smither A.R., Guralnick M.L., Davis N.B., et al. Quantifying the natural history of post-radical prostatectomy incontinence using objective pad test data. BMC Urol 7 (2007) 2-9
4. Matthew A.G., Goldman A., Trachtenberg J., et al. Sexual dysfunction after radical prostatectomy: prevalence, treatments, restricted use of treatments and distress. J Urol 174 (2005) 2105-2110
5. Bhatnagar V., Stewart S.T., Huynh V., et al. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis 9 (2006) 136-146
6. Akduman B., Barqawi A.B., and Crawford E.D. Minimally invasive surgery in prostate cancer: current and future perspectives. Cancer J 11 (2005) 355-361
7. Grubb III R.L., Vardi I.Y., Bhayani S.B., et al. Minimally invasive approaches to localized prostate carcinoma. Hematol Oncol Clin North Am 20 (2006) 879-895
8. Carter H.B., Walsh P.C., Landis P., et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167 (2002) 1231-1234
9. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
10. Villers A., McNeal J.E., Freiha F.S., et al. Multiple cancers in the prostate: morphologic features of clinically recognized versus incidental tumors. Cancer 70 (1992) 2313-2318
11. Miller G.J., and Cygan J.M. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 152 (1994) 1709-1713
12. Djavan B., Susani M., Bursa B., et al. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 5 (1999) 139-142
13. Noguchi M., Stamey T.A., McNeal J.E., et al. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 170 (2003) 459-463
14. Song S.Y., Kim S.R., Ahn G., et al. Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients. Prostate Cancer Prostatic Dis 6 (2003) 143-147
15. Ng J.C., Koch M.O., Daggy J.K., et al. Perineural invasion in radical prostatectomy specimens: lack of prognostic significance. J Urol 172 (2004) 2249-2251
16. Eichelberger L.E., and Cheng L. Does pT2b prostate carcinoma exist?. Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 100 (2004) 2573-2576
17. Horninger W., Berger A.P., Rogatsch H., et al. Characteristics of prostate cancers detected at low PSA levels. Prostate 58 (2004) 232-237
18. Cheng L., Jones T.D., Pan C.X., et al. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18 (2005) 1022-1026
19. Torlakovic G., Torlakovic E., Skovlund E., et al. Volume-related sequence of tumor distribution pattern in prostate carcinoma: importance of posterior midline crossover in predicting tumor volume, extracapsular extension, and seminal vesicle invasion. Croat Med J 46 (2005) 429-435
20. Magi-Galluzzi C., Roma A., Jones S., et al. Pathologic features of single-nodule prostatic carcinoma. [abstract]. Lab Invest 86 (2006) 148A
21. Muezzinoglu B., Frolov A., Ohori M., et al. Clinicopathologic significance of multifocal prostate cancer. [abstract]. Lab Invest 86 (2006) 151A
22. McNeal J.E., Price H.M., Redwine E.A., et al. Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. J Urol 139 (1988) 61-65
23. Stamey T.A., Freiha F.S., McNeal J.E., et al. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71 (1993) 933-938
24. Epstein J.I., Chan D.W., Sokoll L.J., et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160 (1998) 2407-2411
25. Goto Y., Ohori M., Arakawa A., et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156 (1996) 1059-1063
26. Irwin M.B., and Trapasso J.G. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 44 (1994) 862-867 discussion 867-868
27. Chan T.Y., Chan D.Y., Stutzman K.L., et al. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?. J Urol 166 (2001) 2181-2184
28. Noguchi M., Stamey T.A., McNeal J.E., et al. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 166 (2001) 104-109 discussion 109-110
29. Elgamal A.A., Van Poppel H.P., Van de Voorde W.M., et al. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens-a different view. J Urol 157 (1997) 244-250
30. Augustin H., Hammerer P.G., Graefen M., et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 43 (2003) 455-460
31. Miyake H., Sakai I., Harada K., et al. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease. Int J Urol 12 (2005) 270-274
32. Mai K.T., Landry D.C., Yazdi H.M., et al. Identification of isolated and early prostatic adenocarcinoma in radical prostatectomy specimens with correlation to biopsy cores: clinical and pathogenetic significance. Pathol Res Pract 198 (2002) 655-663
33. Eichelberger L.E., Koch M.O., Daggy J.K., et al. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J Clin Pathol 120 (2003) 386-391
34. Barqawi A., and Crawford E.D. Focal therapy in prostate cancer: future trends. BJU Int 95 (2005) 273-274
35. Bostwick D.G., Myers R.P., and Oesterling J. Staging of prostate cancer. Semin Surg Oncol 10 (1994) 60-72
36. Blackwell K.L., Bostwick D.G., Myers R.P., et al. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J Urol 151 (1994) 1565-1570
37. Partin A.W., Chan D.W., Epsetin J.I., et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume, and benign hyperplasia. J Urol 143 (1990) 747-752
38. Stamey T.A., Hay A.R., McNeal J.E., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
39. Kikuchi E., Scardino P.T., Wheeler T.M., et al. Is tumor volume an independent prognostic factor in clinically localized prostate cancer?. J Urol 172 (2004) 508-511
40. Cupp M.R., Bostwick D.G., Myers R.P., et al. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 153 (1995) 1543-1548
41. Ravery V., Schmid H.P., Toublanc M., et al. Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma?. Cancer 78 (1996) 1079-1084
42. Terris M.K., McNeal J.E., and Stamey T.A. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 148 (1992) 829-832
43. McNeal J.E., Bostwick D.G., Kindrachuk R.A., et al. Patterns of progression in prostate cancer. Lancet 1 (1986) 60-63
44. McNeal J.E., Villers A.A., Redwine E.A., et al. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66 (1990) 1225-1233
45. Egawa S., Go M., Kuwao S., et al. Long-term impact of conservative management on localized prostate cancer: a twenty-year experience in Japan. Urology 42 (1993) 520-526 discussion 526-527
46. Chen M.E., Johnston D.A., Tang K., et al. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 89 (2000) 1800-1809
47. Erbersdobler A.F.H., Schnoger S., Graefen M., et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 41 (2002) 40-46
48. Sakai I.H.K., Hara I., Eto H., et al. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones. BJU Int 96 (2005) 528-532
49. Eskicorapci S.Y., Guliyev F., Akdogan B., et al. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 173 (2005) 1536-1540
50. Leibovich B.C., Blute M.L., Bostwick D.G., et al. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology 56 (2000) 726-729
51. Larson T.R., Bostwick D.G., and Corica A. Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Urology 47 (1996) 463-469
52. Lerner S.E., Blute M.L., Bergstralh E.J., et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 156 (1996) 137-143
53. Blute M.L., Bergstralh E.J., Iocca A., et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165 (2001) 119-125
54. Groll R., Fleshner N.E., Sugar L., et al. Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors. Urology 59 (2002) 551-554
55. Makarov D.V., Sanderson H., Partin A.W., et al. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?. J Urol 167 (2002) 2440-2442
56. Vira M.A., Hwang W.-T., D'Amico A.V., et al. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. J Urol 66 (2005) 1015-1019
57. Tollefson M.K., Leibovich B.C., Slezak J.M., et al. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 175 (2006) 547-551
58. Stamey T.A., McNeal J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999) 1395-1400
59. Han M., Snow P.B., Epstein J.I., et al. A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology 56 (2000) 994-999
60. Rasiah K.K., Stricker P.D., Haynes A.M., et al. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer 98 (2003) 2560-2565
61. Sakr W.A., Tefilli M.V., Grignon D.J., et al. Gleason score 7 prostate cancer: a heterogeneous entity?. Correlation with pathologic parameters and disease-free survival. Urology 56 (2000) 730-734
62. Herman C.M., Kattan M.W., Ohori M., et al. Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 25 (2001) 657-660
63. Lau W.K., Blute M.L., Bostwick D.G., et al. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 166 (2001) 1692-1697
64. Chan T.Y., Partin A.W., Walsh P.C., et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 56 (2000) 823-827